- ongoing, recruitingTherapeutic exploratory (Phase II)
Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography, dosefinding study assessing the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder
This study is looking at a new sleep medicine, daridorexant (also known as QUVIVIQ), for young people aged 10-17 who have trouble sleeping (insomnia). It aims to find the right dose and see how well and safely it works to improve sleep.
Germany · Bulgaria · Spain - ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and tolerability of tasipimidine after 3 repeated bed-time doses in patients with insomnia disorder with a 4-week extension part
Finland · Poland · Germany - ongoing, recruitingTherapeutic use (Phase IV)
A multi-center, double-blind, randomized, placebo-controlled, 2-way cross-over post approval study to investigate the efficacy of daridorexant in subjects with insomnia and comorbid nocturia
Spain · Germany